JP2023532444A - 呼吸器病原体を診断し、ｃｏｖｉｄ－１９に関連する転帰を予測する方法 - Google Patents

呼吸器病原体を診断し、ｃｏｖｉｄ－１９に関連する転帰を予測する方法 Download PDF

Info

Publication number
JP2023532444A
JP2023532444A JP2022579814A JP2022579814A JP2023532444A JP 2023532444 A JP2023532444 A JP 2023532444A JP 2022579814 A JP2022579814 A JP 2022579814A JP 2022579814 A JP2022579814 A JP 2022579814A JP 2023532444 A JP2023532444 A JP 2023532444A
Authority
JP
Japan
Prior art keywords
methylation
subject
hla
infection
covid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532444A5 (enExample
Inventor
バーンズ，キャスリーン
ヤン，イバナ
ギグノー，クリストファー
マティアス，ラシカ
ノーマン，ポール
タイエ，アレム
ポレチャ，リシ
バーンズ，ブレット
ピーターソン，ブレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Denver
Original Assignee
University of Colorado Denver
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Denver filed Critical University of Colorado Denver
Publication of JP2023532444A publication Critical patent/JP2023532444A/ja
Publication of JP2023532444A5 publication Critical patent/JP2023532444A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2022579814A 2020-06-23 2021-06-23 呼吸器病原体を診断し、ｃｏｖｉｄ－１９に関連する転帰を予測する方法 Pending JP2023532444A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063042669P 2020-06-23 2020-06-23
US63/042,669 2020-06-23
PCT/US2021/038763 WO2021262894A1 (en) 2020-06-23 2021-06-23 Methods for diagnosing respiratory pathogens and predicting covid-19 related outcomes

Publications (2)

Publication Number Publication Date
JP2023532444A true JP2023532444A (ja) 2023-07-28
JP2023532444A5 JP2023532444A5 (enExample) 2024-07-03

Family

ID=79281779

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579814A Pending JP2023532444A (ja) 2020-06-23 2021-06-23 呼吸器病原体を診断し、ｃｏｖｉｄ－１９に関連する転帰を予測する方法

Country Status (10)

Country Link
US (1) US20240093318A1 (enExample)
EP (1) EP4168593A4 (enExample)
JP (1) JP2023532444A (enExample)
KR (1) KR20230038486A (enExample)
CN (1) CN116096920A (enExample)
AU (1) AU2021297245A1 (enExample)
BR (1) BR112022026509A2 (enExample)
CA (1) CA3184128A1 (enExample)
MX (1) MX2023000105A (enExample)
WO (1) WO2021262894A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4308017A4 (en) * 2021-03-18 2025-02-12 The Board of Trustees of the Leland Stanford Junior University Systems and methods to generate a surgical risk score and uses thereof
EP4303326A1 (fr) * 2022-07-06 2024-01-10 Biomérieux Determination du risque de deces d'un sujet infecte par un virus respiratoire par mesure du niveau d'expression du gene oas2
WO2024008955A1 (en) * 2022-07-08 2024-01-11 Age Labs As Method of screening for severe covid-19 susceptibility
EP4484575A1 (de) * 2023-06-30 2025-01-01 Cerascreen GmbH Markersequenzen zur diagnose und therapiesteuerung von patienten mit testosteron-defizienz

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
WO2001041782A2 (en) 1999-12-09 2001-06-14 Chiron Corporation Method for administering a cytokine to the central nervous system and the lymphatic system
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
AU2001255196A1 (en) 2000-03-29 2001-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing immunogenicity of antigens
WO2002002807A2 (en) * 2000-06-30 2002-01-10 Epigenomics Ag Diagnosis of diseases associated with cell signalling
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7794728B2 (en) 2002-05-29 2010-09-14 The Regents Of The University Of California Attenuated Listeria spp. and methods for using the same
US8337861B2 (en) 2003-01-09 2012-12-25 The Trustees Of The University Of Pennsylvania Compositions, methods and kits for enhancing the immunogenicity of a bacterial vaccine vector
KR101192652B1 (ko) 2003-02-06 2012-10-19 앤저 테라퓨틱스 인코퍼레이티드 비포식 세포로의 침투가 약화된 리스테리아, 리스테리아를 포함하는 백신, 및 그것의 사용방법
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
US7665238B2 (en) 2006-04-03 2010-02-23 S.C. Johnson & Son, Inc. Air freshener with holder
CN101755044B (zh) 2007-05-18 2014-06-11 米迪缪尼有限公司 通过冻干泡沫保存生物活性材料
JP5985397B2 (ja) 2009-11-11 2016-09-06 アドバクシス インコーポレイテッド 組換えリステリア株およびそれを含む免疫原性組成物
EP2521797A4 (en) * 2010-01-04 2013-07-10 Lineagen Inc DNA METHYLATION BIOMARKER FOR LUNG FUNCTION
AU2013266968B2 (en) 2012-05-25 2017-06-29 Emmanuelle CHARPENTIER Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
SG10201700916SA (en) 2012-12-27 2017-03-30 Aduro Biotech Inc Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
CA2955612C (en) 2014-07-18 2022-05-17 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
EP3169355A4 (en) 2014-07-18 2018-07-25 Advaxis, Inc. Listeria-based immunogenic compositions for eliciting anti-tumor responses
MA41218A (fr) 2014-12-19 2017-10-24 Advaxis Inc Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr
BR112019018272A2 (pt) * 2017-03-02 2020-07-28 Youhealth Oncotech, Limited marcadores metilação para diagnosticar hepatocelular carcinoma e câncer
MA47821A (fr) * 2017-03-10 2020-01-15 Self Screen Bv Classificateur de méthylation pour la détection de cancers invasifs induits par le hpv, de cancers gynécologiques et anogénitaux non induits par le hpv et de leurs lésions précurseurs de haut grade

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Time-series plasma cell-free DNA analysis reveals disease severity of COVID-19 patients", MEDRXIV, JPN6025047946, 9 June 2020 (2020-06-09), ISSN: 0005737921 *
BMC BIOINFORMATICS, vol. 15, JPN6025026606, 2014, pages 193, ISSN: 0005631178 *
JOURNAL OF TRANSLATIONAL MEDICINE, vol. 17, JPN6025026607, 2019, pages 345, ISSN: 0005737922 *

Also Published As

Publication number Publication date
US20240093318A1 (en) 2024-03-21
MX2023000105A (es) 2023-04-25
AU2021297245A1 (en) 2023-02-02
EP4168593A1 (en) 2023-04-26
WO2021262894A1 (en) 2021-12-30
EP4168593A4 (en) 2024-11-27
KR20230038486A (ko) 2023-03-20
CN116096920A (zh) 2023-05-09
BR112022026509A2 (pt) 2023-03-07
CA3184128A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
US20240093318A1 (en) Method for diagnosing respiratory pathogens and predicting covid-19 related outcomes
US11091809B2 (en) Molecular diagnostic test for cancer
US20240282449A1 (en) Methods and systems for machine learning analysis of inflammatory skin diseases
US20220399116A1 (en) Systems and methods for assessing a bacterial or viral status of a sample
US20150315643A1 (en) Blood transcriptional signatures of active pulmonary tuberculosis and sarcoidosis
WO2015035367A1 (en) Methods and systems for analysis of organ transplantation
US20240219385A1 (en) Molecular signatures of long-term covid-19 and treatment thereof
US20170247758A1 (en) Methods, computer-readable media, and systems for assessing samples and wounds, predicting whether a wound will heal, and monitoring effectiveness of a treatment
US20160194709A1 (en) DIAGNOSTIC METHOD FOR PREDICTING RESPONSE TO TNFalpha INHIBITOR
US20230340601A1 (en) Transcriptome Analysis For Treating Inflammation
Higham et al. Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease
US12454717B2 (en) Immune profiling using small volume blood samples
CN116134152A (zh) 评估对冠状病毒感染产生严重反应的风险的方法
Duffy Understanding immune variation for improved translational medicine
US20250391505A1 (en) Methods and Systems for Machine Learning Analysis of Lupus Nephritis
Souquette et al. Integrated drivers of basal and acute immunity in diverse human populations
US20170088902A1 (en) Expression profiling for cancers treated with anti-angiogenic therapy
Sacco et al. Multi-omics approach identifies novel age-, time-and treatment-related immunopathological signatures in MIS-C and pediatric COVID-19
CN106119406B (zh) 多发性肉芽肿血管炎及微小动脉炎的基因分型诊断试剂盒及使用方法
US20260117297A1 (en) Longitudinal Gene Expression Analysis of Inflammatory Skin Diseases
EP3825418A2 (en) Molecular signatures for distinguishing liver transplant rejections or injuries
Deng et al. A novel Bayesian framework for harmonizing information across tissues and studies to increase cell type deconvolution accuracy
US20170183735A1 (en) Molecular signatures for distinguishing liver transplant rejections or injuries
Okada et al. POS0312 ENDOGENEOUS HUMAN HERPESVIRUS 6B INTEGRATED IN HUMAN GENOME SEQUENCE ASSOCIATES WITH AFFECTION AND SEVERITY OF SYSTEMIC LUPUS ERYTHEMATOSUS
Cathomas et al. Two distinct immunopathological profiles in autopsy lungs of COVID-19

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240621

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250627

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260421